JP2024535041A5 - - Google Patents
Info
- Publication number
- JP2024535041A5 JP2024535041A5 JP2024516809A JP2024516809A JP2024535041A5 JP 2024535041 A5 JP2024535041 A5 JP 2024535041A5 JP 2024516809 A JP2024516809 A JP 2024516809A JP 2024516809 A JP2024516809 A JP 2024516809A JP 2024535041 A5 JP2024535041 A5 JP 2024535041A5
- Authority
- JP
- Japan
- Prior art keywords
- approximately
- concentration
- composition according
- immunoglobulin
- proline
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202111112052 | 2021-09-18 | ||
| CN202111112052.4 | 2021-09-18 | ||
| PCT/CN2022/119187 WO2023040999A1 (zh) | 2021-09-18 | 2022-09-16 | 包含pd-l1抗原结合片段的组合物及其用途 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2024535041A JP2024535041A (ja) | 2024-09-26 |
| JP2024535041A5 true JP2024535041A5 (enExample) | 2025-09-17 |
Family
ID=85602449
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024516809A Pending JP2024535041A (ja) | 2021-09-18 | 2022-09-16 | Ｐｄ－ｌ１抗原結合断片を含む組成物及びその使用 |
Country Status (7)
| Country | Link |
|---|---|
| US (1) | US20240382411A1 (enExample) |
| EP (1) | EP4403575A4 (enExample) |
| JP (1) | JP2024535041A (enExample) |
| CN (1) | CN118215681A (enExample) |
| AU (1) | AU2022348783A1 (enExample) |
| CO (1) | CO2024009127A2 (enExample) |
| WO (1) | WO2023040999A1 (enExample) |
Family Cites Families (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20030138417A1 (en) * | 2001-11-08 | 2003-07-24 | Kaisheva Elizabet A. | Stable liquid pharmaceutical formulation of IgG antibodies |
| EA039663B1 (ru) * | 2012-05-03 | 2022-02-24 | Амген Инк. | Применение антитела против pcsk9 для снижения сывороточного холестерина лпнп и лечения связанных с холестерином расстройств |
| PL2946765T3 (pl) * | 2014-05-23 | 2017-08-31 | Ares Trading S.A. | Ciekła kompozycja farmaceutyczna |
| CN106397592A (zh) | 2015-07-31 | 2017-02-15 | 苏州康宁杰瑞生物科技有限公司 | 针对程序性死亡配体(pd-l1)的单域抗体及其衍生蛋白 |
| JP7080213B2 (ja) * | 2016-03-23 | 2022-06-03 | スーチョウ トランセンタ セラピューティクス カンパニー，リミテッド | 新規抗ｐｄ－ｌ１抗体 |
| ES2962373T3 (es) * | 2016-04-13 | 2024-03-18 | Medimmune Llc | Uso de aminoácidos como compuestos estabilizadores en composiciones farmacéuticas que contienen altas concentraciones de agentes terapéuticos basados en proteínas |
| US10646569B2 (en) * | 2017-05-16 | 2020-05-12 | Bhami's Research Laboratory, Pvt. Ltd. | High concentration protein formulations with reduced viscosity |
| CN109966487B (zh) * | 2017-12-28 | 2023-08-25 | 上海复宏汉霖生物制药有限公司 | 一种包含抗pd-l1单克隆抗体的药物配制剂 |
| JP2022513693A (ja) * | 2018-11-29 | 2022-02-09 | ハーバー・バイオメド・セラピューティクス・リミテッド | 抗ｐｄ－ｌ１抗体製剤 |
| CN112741804A (zh) * | 2019-10-31 | 2021-05-04 | 上海君实生物医药科技股份有限公司 | 含有抗pd-l1抗体的稳定制剂 |
| TW202130367A (zh) * | 2020-01-15 | 2021-08-16 | 大陸商信達生物製藥（蘇州）有限公司 | 結合ｐｄ－１和ｐｄ－ｌ１的雙特異性抗體的製劑及其用途 |
| MX2022010120A (es) * | 2020-02-18 | 2022-09-05 | Amgen Inc | Formulaciones de anticuerpos anti-tslp humanos y metodos de uso de los mismos. |
| AU2021281152A1 (en) * | 2020-05-28 | 2022-12-22 | Kashiv Biosciences, Llc | An improved process of storing and preparing the protein |
-
2022
- 2022-09-16 CN CN202280062580.XA patent/CN118215681A/zh active Pending
- 2022-09-16 US US18/691,672 patent/US20240382411A1/en active Pending
- 2022-09-16 AU AU2022348783A patent/AU2022348783A1/en active Pending
- 2022-09-16 WO PCT/CN2022/119187 patent/WO2023040999A1/zh not_active Ceased
- 2022-09-16 EP EP22869367.7A patent/EP4403575A4/en active Pending
- 2022-09-16 JP JP2024516809A patent/JP2024535041A/ja active Pending
-
2024
- 2024-07-10 CO CONC2024/0009127A patent/CO2024009127A2/es unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ES2780392T3 (es) | Anticuerpos humanos contra Fel d1 y métodos de uso de los mismos | |
| TWI911431B (zh) | 抗rsv單株抗體配製物 | |
| TWI799757B (zh) | 抗-α4β7抗體之調配物 | |
| JP2015120706A5 (enExample) | ||
| WO2018236904A1 (en) | COMBINATION OF ANTI-CD47 ANTIBODIES AND CELL DEATH INDUCING AGENTS, AND USES THEREOF | |
| CA3060695A1 (en) | Stable formulations of anti-ctla4 antibodies alone and in combination with programmed death receptor 1 (pd-1) antibodies and methods of use thereof | |
| KR20160079890A (ko) | 항체-약물 접합체 동결건조 제제 | |
| CN115666649B (zh) | 一种新型冠状病毒抗体的药物组合物及其用途 | |
| US8617548B2 (en) | Methods of preventing or treating anthrax using anti-anthrax antibodies | |
| CA3173919A1 (en) | Use of a multimeric anti-dr5 binding molecule in combination with a cancer therapy for treating cancer | |
| ES2699078T3 (es) | Proteínas de unión a antigeno específicas para componente amiloide sérico P | |
| US20220144929A1 (en) | Anti-sema3a antibodies and their uses for treating eye or ocular diseases | |
| AU2021332460A1 (en) | Methods and compositions to treat autoimmune diseases and cancer | |
| CN110960490A (zh) | 一种抗egfr抗体偶联药物组合物及其用途 | |
| CN110305214A (zh) | 新型抗cd47抗体 | |
| CN118382463A (zh) | 一种包含抗CD79b抗体药物偶联物的药物组合物及其用途 | |
| CN117159703B (zh) | 含抗lag-3抗体的药物组合物及其用途 | |
| WO2022051223A1 (en) | Use of sars-cov-2 receptor binding motif (rbm)-reactive monoclonal antibodies to treat covid-19 | |
| KR20250110257A (ko) | Hgfr 및 egfr에 특이적으로 결합하는 이중특이성 항체를 포함하는 약학적 조성물 | |
| TW202144406A (zh) | ＳＡＲＳ－ＣｏＶ－２抗體及其應用 | |
| CN116096746A (zh) | 多瘤病毒中和抗体的给药 | |
| KR20200012937A (ko) | c-Met 항체 약물 접합체를 포함하는 약학 조성물 및 그의 용도 | |
| CN114729045A (zh) | 对糖基化的ctla-4特异性的抗体及其使用方法 | |
| TWI877179B (zh) | 抗-angpt2抗體 | |
| IL295958A (en) | Protease-processed molecules |